RESULTS	Median OS was 23.3 months with bevacizumab plus IFN and 21.3 months with IFN plus placebo ( unstratified hazard ratio [ HR ] = 0.91 ; 95 % CI , 0.76 to 1.10 ; P = .3360 ; stratified HR = 0.86 ; 95 % CI , 0.72 to 1.04 ; P = .1291 ) .\